Contrast Horizon Technology Finance (NASDAQ:HRZN) and Tekla Life Sciences Investors (NYSE:HQL)


Horizon Technology Finance ( NASDAQ:HRZN – Get Rating ) and Tekla Life Sciences Investors ( NYSE:HQL – Get Rating ) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Internal and institutional ownership

11.3% of Horizon Technology Finance shares are held by institutional investors. Comparatively, 20.7% of Tekla Life Sciences Investors shares are held by institutional investors. 1.5% of Horizon Technology Finance shares are held by insiders. Comparatively, 10.1% of Tekla Life Sciences Investors shares are held by insiders. Strong institutional ownership is an indicator that endowments, hedge funds and big money managers believe a company is poised for long-term growth.

Analyst recommendations

This is a summary of the latest recommendations for Horizon Technology Finance and Tekla Life Sciences Investors, as provided by MarketBeat.com.

Appraisals for sale Keep the ratings Buy Ratings Strong shopping reviews Evaluation result
Horizon Technology Finance 0 2 0 0 2.00
Tekla Life Sciences Investors 0 0 0 0 N/A

Horizon Technology Finance presently has a consensus price target of $15.50, indicating a potential upside of 29.60%. Given Horizon Technology Finance’s higher possible upside, equities analysts clearly believe Horizon Technology Finance is more favorable than Tekla Life Sciences Investors.

Risk and volatility

Horizon Technology Finance has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Comparatively, Tekla Life Sciences Investors has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500 .

Earnings & Rating

This table compares Horizon Technology Finance and Tekla Life Sciences investors’ gross revenue, earnings per share and valuation.

Gross income Price/sales ratio Net income Earnings per share Price/earnings ratio
Horizon Technology Finance 60.01 million dollars 4.78 27.78 million dollars $1.24 9.65
Tekla Life Sciences Investors N/A N/A N/A N/A N/A

Horizon Technology Finance has higher revenue and earnings than Tekla Life Sciences Investors.

profitability

This chart compares Horizon Technology Finance and Tekla Life Sciences’ investor net margins, return on equity and return on assets.

Net margins Return on capital Return of assets
Horizon Technology Finance 41.45% 11.32% 5.55%
Tekla Life Sciences Investors N/A N/A N/A

dividends

Horizon Technology Finance pays an annual dividend of $1.20 per share and has a dividend yield of 10.0%. Tekla Life Sciences Investors pays an annual dividend of $1.59 per share and has a dividend yield of 10.5%. Horizon Technology Finance pays out 96.8% of its earnings in the form of a dividend, suggesting that it may not have enough earnings to cover future dividend payments.

summary

Horizon Technology Finance beats Tekla Life Sciences Investors in 6 of 10 factors compared between the two stocks.

About Horizon Technology Finance (Get rating)

Horizon Technology Finance Corporation is a business development company specializing in lending and investing in development stage investments. It focuses on making secured debt investments and lending to venture capital-backed companies in the technology, life science, health care information and services, and clean technology industries. It seeks to invest in companies in the United States.

About Tekla Life Sciences Investors (Get rating)

Tekla Life Sciences Investors is a closed-end equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical devices, hospitals, healthcare information technology and services, equipment and supplies industries, as well as in the agriculture industry and environmental management. The fund invests primarily in growth stocks of small-cap companies. It uses fundamental analysis focusing on factors such as market position for services or products, business management experience, technological expertise, and the ability to generate funds internally to finance growth or to secure external sources of capital to create her portfolio. The fund benchmarks its portfolio’s performance against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as the H&Q Life Sciences Investor Fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.



Get News and Reviews for Horizon Technology Finance Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Horizon Technology Finance and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.